Quarterly ResultAug 5, 2026, 04:18 PM
Schrodinger Swings to Q2 Profit; Drug Discovery Revenue Up
AI Summary
Schrodinger, Inc. reported a significant turnaround in Q2 2026, achieving a net income of $5.98 million compared to a substantial loss in the prior year. Total revenues increased to $58.89 million, driven by strong growth in drug discovery revenue, despite a decline in software product and services revenue. The company also saw a positive change in the fair value of equity investments, contributing to the improved financial performance.
Key Highlights
- Q2 2026 Net Income: $5.98 million, a swing from a $43.17 million loss in Q2 2025.
- Q2 2026 Basic EPS: $0.08, up from $(0.59) in Q2 2025.
- Q2 2026 Total Revenues: $58.89 million, up from $54.76 million in Q2 2025.
- Q2 2026 Drug Discovery Revenue: $22.99 million, up from $13.94 million in Q2 2025.
- Q2 2026 Software Products and Services Revenue: $32.54 million, down from $36.03 million.
- YTD 2026 Net Loss: Reduced to $54.05 million from $102.98 million in YTD 2025.
- Q2 2026 Change in Fair Value of Equity Investments: $45.87 million, up from $4.58 million.
- Cash and cash equivalents at June 30, 2026: $287.85 million.
Price Impact
More from SDGR